Acute respiratory distress syndrome : To correct interstitial pulmonary edema (in combination with diuretics) and hypoproteinemia associated with acute respiratory distress syndrome.
Cirrhotic ascites, therapeutic paracentesis (adjunctive agent):To maintain intravascular volume following removal of large-volume paracentesis in cirrhotic patients.
Hypovolemia:Plasma volume expansion and maintenance of intravascular volume in select patients for the treatment of hypovolemia (with or without shock). For replacement of volume deficit, 5% solution is generally preferred.
Neonatal hemolytic disease:Binds and detoxifies unconjugated bilirubin in severe hemolytic disease of the newborn during exchange transfusion.
Nephrosis (acute) (adjunctive agent):Treatment of edema in patients with acute nephrosis in combination with diuretics.
Ovarian hyperstimulation syndrome, treatment :As a plasma volume expander in fluid management for the treatment of severe ovarian hyperstimulation syndrome.
Plasma exchange, therapeutic::To avoid excessive hypoproteinemia, during certain types of exchange transfusion, or with the use of very large volumes or previously frozen or washed red cells.

Blood Product Derivative; Plasma Volume Expander, Colloid:
Provides increase in intravascular oncotic pressure and causes mobilization of fluids from interstitial into intravascular space

Half-life Elimination:15 to 20 days

Hypersensitivity to albumin or any component of the formulation; severe anemia, heart failure; patients at risk of volume overload (eg, patients with kidney insufficiency, severe anemia, stabilized chronic anemia, or heart failure); dilution with sterile water for injection (may cause hemolysis or acute kidney failure)

Use in pregnant patients may be considered when contraindications to nonprotein colloids exist

1.Endogenous albumin is present in breast milk.
2.According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.

Frequency not defined:
Cardiovascular: Flushing, heart failure, hypotension, tachycardia
Dermatologic: Pruritus, skin rash, urticaria
Gastrointestinal: Nausea, vomiting
Nervous system: Chills, rigors
Respiratory: Bronchospasm, dyspnea, pulmonary edema
Miscellaneous: Fever
Post marketing:
Cardiovascular: Acute myocardial infarction, atrial fibrillation
Endocrine & metabolic: Hyperchloremic metabolic acidosis
Gastrointestinal: Dysgeusia, sialorrhea
Hypersensitivity: Anaphylactic shock, anaphylaxis , hypersensitivity reaction , nonimmune anaphylaxis , type 1 hypersensitivity reaction
Nervous system: Headache
Miscellaneous: Febrile reaction

Usual dose:
25 g; initial dose may be repeated in 15 to 30 minutes if response is inadequate.
Adult respiratory distress syndrome:
25 g over 30 minutes (in combination with furosemide); may repeat at 8 hours (if necessary) for 3 days
Cirrhotic ascites, therapeutic paracentesis (adjunctive agent):
5 to 10 g for every liter removed (usual dose cited: 8 g for every liter removed) or 50 g total for paracentesis >5LHypovolemia:
Initial: 12.5 to 25 g (250 to 500 mL)repeat after 15 to 30 minutes as needed (if hemodynamic stability is not achieved).
Ovarian hyperstimulation syndrome:
IV: 50 to 100 g over 4 hours; repeat at 4 to 12 hours intervals as needed.

Should be used in patients with fluid or sodium restrictions (eg, patients with hypoproteinemia and generalized edema, or nephrotic syndrome).
Dose depends on condition of patient.

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

儲存於20-25℃，運送溫度15-30℃。